Back to search

Article

Study Protocol for Prospective Multi-Institutional Phase III Trial of Standard of Care Therapy with or without Stereotactic Ablative Radiation Therapy for Recurrent Ovarian Cancer (SABR-ROC)

2023-08-17

Abstract excerpt

<h4>Background: </h4> Efforts have been made to investigate the role of salvage radiotherapy (RT) in treating recurrent ovarian cancer (ROC). Stereotactic ablative radiation therapy (SABR) is a state-of-the-art therapy that uses intensity modulation to increase the fractional dose, decrease the number of fractions, and target tumors with high precision. Methods The SABR-ROC trial is a phase 3, multicenter, random...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
09f17600-0148-56d5-903e-7350b010dd23
DOI
10.21203/rs.3.rs-3191582/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Study Protocol for Prospective Multi-Institutional Phase III Trial of Standard of Care Therapy with or without Stereotactic Ablative Radiation Therapy for Recurrent Ovarian Cancer (SABR-ROC)DOI 10.21203/rs.3.rs-3191582/v1
Stereotactic Body Radiation Therapy for Oligoprogressive Ovarian Cancer Patients Treated During Poly(ADP-Ribose)-Polymerase Inhibitor Maintenance: Efficacy and Adverse Events From the Epimetheo Retrospective StudySemantic proximity
Comparing efficacy and safety of Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Bayesian network meta-regression analysesSemantic proximity
Platinum-Based Chemotherapy Versus Secondary Cytoreductive Surgery Before Olaparib Maintenance Therapy for 259 Patients with BRCA Mutated Platinum-Sensitive Recurrent Ovarian Cancer: A Multicenter Retrospective Study: Comparative Effectiveness and Survival Outcomes Analysis.Semantic proximity
Does stereotactic body radiation therapy with image guidance technology improve treatment outcomes in intra-pulmonary metastasis patients? A randomized controlled studySemantic proximity
Radiotherapy Combined with Raltitrexed and Irinotecan for Treating Unresectable Recurrent Colorectal CancerSemantic proximity
Stereotactic body radiation therapy is beneficial for a subgroup of patients with urothelial cancer and solitary metastatic disease: a single institution real-world experienceSemantic proximity
Notable-HCC: A phase Ib trial of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with early stage resectable hepatocellular carcinomaSemantic proximity
Efficacy and Safety of Bevacizumab-Combined Single-Agent Chemotherapy for Platinum-Resistant Ovarian Cancer that Recurred During PARP Inhibitor TreatmentSemantic proximity
Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer (LBA 6)Semantic proximity
Optimizing bevacizumab dosing in first-line ovarian cancer treatment: The PGOG-ov1 trial.Semantic proximity
Long-term outcomes of stereotactic ablative brachytherapy for recurrent aggressive fibromatosis: an eight-year retrospective multicenter studySemantic proximity
SABR-Dual: A phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancerSemantic proximity
Select a neighboring publication to make it the new centre.